Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

ph I binutuzumab, venetoclax, and lenalidomide in relapsed/refractory B-cell non-Hodgkin lymphoma

Protocol: OSU-16187

Full Title

A phase I study of obinutuzumab, venetoclax, and lenalidomide in relapsed and refractory B-cell non-Hodgkin lymphoma

Non-Hodgkin’s Lymphoma (B- & T-Cell) Lymphoma